U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H8N4.ClH
Molecular Weight 196.637
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDRALAZINE HYDROCHLORIDE

SMILES

Cl.NNC1=NN=CC2=C1C=CC=C2

InChI

InChIKey=ZUXNZUWOTSUBMN-UHFFFAOYSA-N
InChI=1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5H,9H2,(H,11,12);1H

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/hydralazine.html

Hydralazine is a direct-acting vasodilator that is used as an antihypertensive agent. Hydralazine works by relaxing blood vessels (arterioles more than venules) and increasing the supply of blood and oxygen to the heart while reducing its workload. It also functions as an antioxidant. It inhibits membrane-bound enzymes that form reactive oxygen species, such as superoxides. Excessive superoxide counteracts NO-induced vasodilation. Hydralazine is used for the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia.

CNS Activity

CNS Penetrant
2554
Curator's Comment: some metabolites of hydralazine are known to cross the blood-brain barrier

Originator

Washington University
2
Curator's Comment: In 1951 the Hypertension Division at Washington University initiated the use of hydralazine

Approval Year

1953
193
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Inhibitor
8297
 400.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Hydralazine Hydrochloride

Approved Use

Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.

Launch Date

1985
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6653641
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: HYDRALAZINE
HYDRALAZINE
 HYDRALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
407 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6653641
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: HYDRALAZINE
HYDRALAZINE
 HYDRALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6653641
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: HYDRALAZINE
HYDRALAZINE
 HYDRALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
13%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
HYDRALAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Co-administed with::
ethanol
Sources:
https://pubmed.ncbi.nlm.nih.gov/1536497
unhealthy, 27
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 27
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1536497
Disc. AE: Tachycardia...
AEs leading to
discontinuation/dose reduction:
Tachycardia
Sources:
https://pubmed.ncbi.nlm.nih.gov/1536497
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30821162
Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/30821162
Page: p.53, 54
Disc. AE: Lethargy, Hypotension...
AEs leading to
discontinuation/dose reduction:
Lethargy
Hypotension
Tachycardia
Chest pain
Sources:
https://pubmed.ncbi.nlm.nih.gov/30821162
Page: p.53, 54
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://www.medicines.org.uk/emc/product/4527
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.medicines.org.uk/emc/product/4527
Disc. AE: Skin rash, Febrile reaction...
AEs leading to
discontinuation/dose reduction:
Skin rash (rare)
Febrile reaction (rare)
Sources:
https://www.medicines.org.uk/emc/product/4527
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.2
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.2
Disc. AE: Systemic lupus erythematosus synd, Glomerulonephritis...
AEs leading to
discontinuation/dose reduction:
Systemic lupus erythematosus synd
Glomerulonephritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.2
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.3
Disc. AE: Angina pectoris, Myocardial infarction...
AEs leading to
discontinuation/dose reduction:
Angina pectoris
Myocardial infarction
Peripheral neuritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.3
40 mg single, intravenous
Recommended
Dose: 40 mg
Route: intravenous
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
Page: p.1
Disc. AE: Systemic lupus erythematosus synd, Glomerulonephritis...
AEs leading to
discontinuation/dose reduction:
Systemic lupus erythematosus synd
Glomerulonephritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
Page: p.1
AEs

AEs

AESignificanceDosePopulation
Tachycardia Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Co-administed with::
ethanol
Sources:
https://pubmed.ncbi.nlm.nih.gov/1536497
unhealthy, 27
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 27
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1536497
Chest pain Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30821162
Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/30821162
Page: p.53, 54
Hypotension Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30821162
Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/30821162
Page: p.53, 54
Lethargy Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30821162
Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/30821162
Page: p.53, 54
Tachycardia Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30821162
Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/30821162
Page: p.53, 54
Febrile reaction rare
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://www.medicines.org.uk/emc/product/4527
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.medicines.org.uk/emc/product/4527
Skin rash rare
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://www.medicines.org.uk/emc/product/4527
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.medicines.org.uk/emc/product/4527
Glomerulonephritis Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.2
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.2
Systemic lupus erythematosus synd Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.2
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.2
Angina pectoris Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.3
Myocardial infarction Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.3
Peripheral neuritis Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
Page: p.3
Glomerulonephritis Disc. AE
40 mg single, intravenous
Recommended
Dose: 40 mg
Route: intravenous
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
Page: p.1
Systemic lupus erythematosus synd Disc. AE
40 mg single, intravenous
Recommended
Dose: 40 mg
Route: intravenous
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1767
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2B6
810

CYP2C8
911

CYP2C19
1478

CYP3A
214

aldehyde oxidase
7

CYP2A6
707

BSEP
402

OCT1
512

OATP1B1
788

OATP1B3
706
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
BSEP
403
 no [IC50 >1000 uM]
CYP2A6
739
 no
CYP2C19
1553
 unlikely
CYP2C8
965
 unlikely
CYP2C9
1819
 unlikely
OCT1
543
 unlikely
CYP3A4
1925
 yes [IC50 197 uM]
aldehyde oxidase
8
 yes [Ki 83 uM]
CYP1A2
1692
 yes
CYP2B6
1001
 yes
CYP2D6
1891
 yes
CYP3A
298
 yes
OATP1B1
803
 yes
OATP1B3
715
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5775
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5775
ChemicalBook
CB1855362
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1855362
MolPort
MolPort-000-876-738
https://www.molport.com/shop/molecule-link/MolPort-000-876-738
ZINC
ZINC000012360535
http://zinc15.docking.org/substances/ZINC000012360535
eMolecules
1978120
https://www.emolecules.com/cgi-bin/more?vid=1978120
eMolecules
975874
https://www.emolecules.com/cgi-bin/more?vid=975874
PubMed

PubMed

TitleDatePubMed
Clinical consequences of polymorphic acetylation of basic drugs.
1977 Sep
Immunological side-effects of antihypertensive drugs.
1979
Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
1985 Mar
Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model.
1985 Sep 27
Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug.
1985 Sep-Oct
Drug-associated glomerulopathies.
1986
Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
1986
Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
1986
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
1986 Jun
Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.
1987 Apr
Isolated minimal change nephropathy associated with diclofenac.
1987 Jul 18
Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.
1987 May
Hydralazine-induced cholestatic jaundice following liver transplantation.
1989 Jan
Myocardial ischemia during isoflurane anesthesia: the effect of substituting halothane.
1989 Jun
Features of the acute hypotensive action of carvedilol and its ameliorating effect on myocardial ischemia.
1991
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
1991 Aug 1
Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
1991 Mar
Phaeochromocytoma: an unusual cause of hypertension in pregnancy.
2001 Jan
Drugs for treatment of very high blood pressure during pregnancy.
2002
Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity.
2002 Aug
[Pulmonary hypertension and pregnancy].
2002 Feb
Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia.
2002 Jan
High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter.
2002 Jun
Analyses of differential gene expression in genetic hypertensive rats by microarray.
2002 Mar
Tight blood pressure control decreases apoptosis during renal damage.
2004 Mar
Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine.
2005 Aug
Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system.
2005 Jan
Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine.
2006 Aug 7
Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II.
2006 Dec
Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo.
2006 Jan
Hydralazine inhibits rapid acrolein-induced protein oligomerization: role of aldehyde scavenging and adduct trapping in cross-link blocking and cytoprotection.
2006 Mar
Differential expression of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension.
2006 Mar
Antihypertensive drugs clonidine, diazoxide, hydralazine and furosemide regulate the production of cytokines by placentas and peripheral blood mononuclear cells in normal pregnancy.
2006 May
Persistent hypertension and progressive renal injury induced by salt overload after short term nitric oxide inhibition.
2007 Dec
The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
2007 Feb 26
D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease.
2007 Nov
Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis.
2008
Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.
2008 Dec
The prince and the pauper. A tale of anticancer targeted agents.
2008 Oct 23
Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension.
2008 Sep
Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart.
2009 Feb 14
"Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
2009 Jan
Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation.
2009 Jan 1
Hydralazine-induced cholestatic hepatitis.
2009 Jul-Aug
Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis.
2009 Jun
D-penicillamine-induced autoimmunity: relationship to macrophage activation.
2009 Sep
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway.
2011 May
Diesel exhaust induced pulmonary and cardiovascular impairment: the role of hypertension intervention.
2013 Apr 15
Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity.
2013 Feb 25
Patents

Patents

07989452
2
JP2003507418A
31
JP2011513274A
3
JP2011528275A
455
JPS55160769A
2

Sample Use Guides

In Vivo Use Guide
Curator's Comment: can also be used intramuscularly or as a rapid intravenous bolus injection directly into the vein. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
Initial dose: 10 mg orally 4 times a day for the first 2 to 4 days. Increase to 25 mg orally 4 times a day for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg orally 4 times a day.
Route of Administration: Oral
In Vitro Use Guide
Hydralazine (0.03-10 mmol.L(-1)) inhibited the activities of both PKA and PKG with IC50 of 1.2 and 2.5 mmol.L(-1), respectively
Name Type Language
HYDRALAZINE HYDROCHLORIDE
EP   HSDB   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
HYDRALAZINE HYDROCHLORIDE [JAN]
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE
Common Name English
HYDRALAZINE HYDROCHLORIDE [USP-RS]
Common Name English
HYDRALAZINE HYDROCHLORIDE [WHO-IP]
Common Name English
APRESOLINE-ESIDRIX COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
SER-A-GEN COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
DRALZINE
Brand Name English
UNIPRES COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF APRESAZIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF SERPASIL-APRESOLINE
Common Name English
HYDROSERPINE PLUS (R-H-H) COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
SER-AP-ES COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF UNIPRES
Common Name English
PHTHALAZINE, 1-HYDRAZINO-, MONOHYDROCHLORIDE
Common Name English
APRESSINUM [WHO-IP]
Common Name English
MC-1101
Code English
HYDRALAZINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
APRESAZIDE COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRA-ZIDE COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRAP-ES COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF SER-A-GEN
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF HYDROSERPINE PLUS (R-H-H)
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF CAM-AP-ES
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF HYDRA-ZIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE [MART.]
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF HYDRAP-ES
Common Name English
DRALSERP COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE [USP IMPURITY]
Common Name English
HYDRALAZINE HCL
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF DRALSERP
Common Name English
HYDRALAZINE HYDROCHLORIDE [HSDB]
Common Name English
SERPASIL-APRESOLINE COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
CAM-AP-ES COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
1-Hydrazinophthalazine monohydrochloride
Systematic Name English
HYDRALAZINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF SER-AP-ES
Common Name English
HYDRALAZINE HYDROCHLORIDE [MI]
Common Name English
APRESOLINE
Brand Name English
Hydralazine hydrochloride [WHO-DD]
Common Name English
HYDRALAZINE HYDROCHLORIDE [VANDF]
Common Name English
BIDIL COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF APRESOLINE-ESIDRIX
Common Name English
NSC-89394
Code English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF BIDIL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C270
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
HYDRALAZINE HYDROCHLORIDE
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Soluble in 25 parts of water; slightly soluble in ethanol (~750 g/l) TS; very slightly soluble in ether R. Category: Antihypertensive drug. Storage: Hydralazine hydrochloride should be kept in a well-closed container, protected from light. Additional information: Hydralazine hydrochloride melts at about 275 ?C with decomposition. Even in the absence of light, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Hydralazine hydrochloride contains not less than 98.0% and not more than 101.0% of C8H8N4,HCl, calculated with reference to the dried substance.
DAILYMED
FD171B778Y
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
ChEMBL
CHEMBL276832
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
ECHA (EC/EINECS)
206-151-0
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
RXCUI
82027
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID1044645
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
HSDB
434
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
MERCK INDEX
m6072
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C551
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
EVMPD
SUB02553MIG
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
NSC
89394
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
CAS
304-20-1
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
CHEBI
31672
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
SMS_ID
100000091656
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
FDA UNII
FD171B778Y
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
PUBCHEM
9351
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
DRUG BANK
DBSALT000792
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
RS_ITEM_NUM
1313006
Created by admin on Fri Dec 15 14:58:21 GMT 2023 , Edited by admin on Fri Dec 15 14:58:21 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of HYDRALAZINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966